Two Sigma Advisers
MLTX icon

Two Sigma Advisers’s MoonLake Immunotherapeutics MLTX Stock Holding History

Two Sigma Advisers’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-131,700
Closed -$1.74M – 1298
2025
Q4 		$1.74M Buy
131,700
+92,376
+235% +$1.09M ﹤0.01% 1241
2025
Q3 		$282K Buy
+39,324
New +$2.05M ﹤0.01% 2017
2025
Q2 		– Sell
-25,400
Closed -$992K – 2446
2025
Q1 		$992K Buy
+25,400
New +$1.09M ﹤0.01% 1474

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Advisers's MLTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 131,700 shares — an estimated $1.74M sold.

Two Sigma Advisers first reported a position in MLTX in Q1 2025 and held it in 3 quarters. The position peaked at $1.74M in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 131,700 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $1.74M.
  • Two Sigma Advisers first reported a position in MoonLake Immunotherapeutics in Q1 2025 and held it in 3 quarters.
  • Two Sigma Advisers's MoonLake Immunotherapeutics position peaked at $1.74M in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.